UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 28, 2014

ANI PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware	**001-31812**	**58-2301143**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(I.R.S. Employer Identification Number)**
210 Main Street West Baudette, Minnesota		**56623**
(Address of principal executive offices)		**(Zip Code)**

Registrant's telephone number, including area code: (218) 634-3500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see General Instruction A.2. below*):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On February 28, 2014, ANI Pharmaceuticals, Inc. (the "Company") posted to its website its March 2014 Corporate Presentation. The presentation is available on the Company's website, www.anipharmaceuticals.com, and is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated into this Item 7.01 by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Forward-Looking Statements

Certain statements contained in the presentation slides furnished with this report contain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the potential benefits of the recent Merger, the Company's plans, objectives, expectations and intentions with respect to future operations and products, the anticipated financial position, operating results and growth prospects of the Company and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "plans," "potential," "future," "believes," "intends," "continue," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, subject to change. You should not place undue reliance on those statements because they are subject to numerous uncertainties, risks and other factors relating to the Company's operations and business environment and other factors, all of which are difficult to predict and many of which are beyond the Company's control.

Uncertainties and risks may cause the Company's actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to, the risk that the Company may in the future face increased difficulty in importing raw materials and/or increased competition, for its Esterified Estrogen with Methyltestosterone Tablet product; competitive conditions for the Company's other products may intensify; the Company may be required to seek the approval of the U.S. Food and Drug Administration ("FDA") for its unapproved products or withdraw such products from the market; general business and economic conditions; the Company's expectations regarding trends in markets for the Company's current and planned products; the Company's future cash flow and its ability to support its operations; the Company's ability to obtain additional financing as needed; the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance of such products; and the marketing success of the Company's licensees or sublicensees.

These factors should not be construed as exhaustive and should be read in conjunction with the Company's other disclosures, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on February 28, 2014, including the factors described in "Item 1A. Risk Factors." Other risks may be described from time to time in our filings made under the securities laws, including our quarterly reports on Form 10-Q and our current reports on Form 8-K. There may be additional risks, uncertainties and factors that we do not currently view as material or that are not known. The forward-looking statements contained in this document are made only as of the date of this document. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Exhibit
99.1	ANI Pharmaceuticals, Inc. Corporate Presentation March 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANI PHARMACEUTICALS, INC.

Date: February 28, 2014

By: /s/ Charlotte C. Arnold
Charlotte C. Arnold
Vice President and Chief Financial Office

ani Pharmaceuticals, Inc.

A Specialty Pharmaceutical Company

NASDAQ: ANIP

HIGH POTENCY DRUGS – NARCOTIC DRUGS – RX LIQUIDS AND TABLETS – CONTRACT MANUFACTURING

Corporate Presentation

March 2014

Cautionary Statement Concerning Forward-Looking Statements

This presentation may contain forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the Company's plans, objectives, expectations and intentions with respect to future operations and products, the anticipated financial position, operating results and growth prospects of the Company and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "plans," "potential," "future," "believes," "intends," "continue," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause the Company's actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks may cause the Company's actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to, the risk that the Company may in the future face increased difficulty in importing raw materials and/or increased competition, for its Esterified Estrogen with Methyltestosterone Tablet product; competitive conditions for the Company's other products may intensify; the Company may be required to seek the approval of the U.S. Food and Drug Administration ("FDA") for its unapproved products or withdraw such products from the market; general business and economic conditions; the Company's expectations regarding trends in markets for the Company's current and planned products; the Company's future cash flow and its ability to support its operations; the Company's ability to obtain additional financing as needed; the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance of such products; and the marketing success of the Company's licensees or sublicensees. More detailed information on these and additional factors that could affect the Company's actual results are described in the Company's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K filed with the Securities and Exchange Commission February 28, 2014. All forward-looking statements in this presentation speak only as of the date made and are based on the Company's current beliefs and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

ani Pharmaceuticals, Inc.

Leadership – Deep Industry Experience

Senior Management	ANI Since	Previous Affiliation
Arthur S. Przybyl, CEO	2009	Akorn (NASDAQ: AKRX)
Charlotte C. Arnold, CFO	2009	MVP Capital Partners
Robert J. Jamnick, VP Quality and PD	2007	Solvay
James G. Marken, VP Operations	2007	Solvay
Robert W. Schrepfer, VP BD	2013	Healthcare Value Capital
Gary L. Cannizaro, Senior Dir. National Accounts	2005	Akorn (NASDAQ: AKRX)

Board of Directors	Member Since	Current Affiliation
Robert E. Brown, Jr. Chairman	2009	MVP Capital Partners
Arthur S. Przybyl, CEO	2009	ANI Pharmaceuticals
Fred Holubow	2013	William Harris Investors
Ross Mangano	2013	Oliver Estate
Tracy Marshbanks	2006	First Analysis
Thomas A. Penn	2009	MVP Capital Partners
Daniel Raynor	2013	Argentum

ani Pharmaceuticals, Inc.

ANI Mission Statement

ANI Pharmaceuticals is an integrated specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals.

ANI's mission is to develop, manufacture, and market niche generic pharmaceuticals, focusing on opportunities in pain management (narcotics), anti-cancer (oncolytics), women's health (hormones and steroids), and complex formulations including extended release and combination products.

ani Pharmaceuticals, Inc.

ANI Overview – Poised for Growth

- ANI Today
  - Core competencies: marketing and manufacturing
  - Two manufacturing facilities: narcotics and potent compounds
  - Experienced management team
  - Existing business + potential future royalty + new products + potential acquisitions
    - For the year ended December 31, 2013: $30.1 million total net revenues
      - $22.7 million ANI Rx product revenues
      - $7.4 million contract manufacturing/services revenues
      - Annual organic growth 48% year/year
    - Potential future royalty stream via partnership with Teva
    - 13 products in development; total current market $910 million(1)
    - 31 products acquired from Teva; total current market $860 million(1)

ani Pharmaceuticals, Inc.

(1) Based on Company estimates, and recent IMS and NSP Audit data

ANI Recent History and Highlights

2009	New executive management team: Art Przybyl, CEO and Charlotte Arnold, CFO
2010	New management expands ANI strategy to include ANI labeled Rx products
2011	ANI expands marketed Rx portfolio to seven products through internal development and acquisition
2013	ANI completes merger with BioSante Pharmaceuticals and obtains NASDAQ Global Market listing (NASDAQ: ANIP), June 2013
2013	Announces agreement to acquire 31 previously marketed generic products from Teva for $12.5 million and a percentage of future gross profits, December 2013

Summary of Biosante Transaction

- Acquired potential future royalty on generic Androgel™ via Teva partnership
- Transaction netted $18 million in cash
- Public listing enables easier access to markets for future expansion
- ANI shareholders owned 57% of company post-merger

ani Pharmaceuticals, Inc.

Sales and Marketing / Financial Overview

ANI Historical Revenue Growth

$s in millions



Cost of sales as a percentage of net revenues, excluding depreciation and amortization

ANI Current Rx Product Portfolio

Generic Products	Position	Market Share[1]
EE/MT Tablets	#1	90%
Fluvoxamine Tablets	#1	55%
HC Enema	#1	85%
Metoclopramide Solution	#2	31%
Opium Tincture	#1	75%

Branded Products

Cortenema™

Reglan Tablets™

(1) Based on Company estimates, and recent IMS and NSP Audit data

ANI Rx Portfolio Prescription Volumes



ani Pharmaceuticals, Inc.

Source: IMS Health

ANI Contract Manufacturing and Royalties

- Current Business
  - $7.4 million in contract manufacturing and services revenues during the twelve-month period ended December 31, 2013
  - Six customers
    - Twelve products and sixteen SKUs
- Future Opportunities
  - One contract customer awaiting FDA approval
    - One product and two SKUs
  - Potential future royalty: Teva's generic Androgel™

ani Pharmaceuticals, Inc.

ANI 2013 Financial Highlights

Annual Results - 2013

($ in millions)	Twelve months ended		
	December 31, 2013	December 31, 2012	% Growth
Net Revenues	$30.1	$20.4	48%
Adjusted non-GAAP EBITDA(1)	$7.5	$1.5	436%

Quarterly Results – 4th Quarter 2013

($ in millions)	Three months ended		
	December 31, 2013	December 31, 2012	% Growth
Net Revenues	$10.5	$5.3	98%
Adjusted non-GAAP EBITDA(1)	$3.9	$(0.3)	N/A
Net Income from Cont. Ops.	$3.4	$(1.2)	N/A
EPS from Cont. Ops.	$0.35	N/A	

ani Pharmaceuticals, Inc.

(1) Please see page 20 for US GAAP reconciliation

Product Development / Business Development Overview

ani Pharmaceuticals, Inc.

ANI Product Development Highlights

- Development Pipeline: 13 products in development
  - Five filed ANDAs, Eight ANDAs in progress
    - Development partners: Ricon, Sofgen, Sterling
  - Total combined current market: $910 million(1)

Therapeutic Category	Filed	In Development	Market Size(1) ($M)
Oncolytics and Narcotics	3	2	$97 million
Other (Extended Release, Combination Products)	2	6	$813 million

- Acquired Pipeline: 31 previously marketed generic products
  - Acquired from Teva
  - 20 solid-oral immediate release products, 7 liquid products and 4 extended release products
  - Total combined current market: $860 million(1)

ani Pharmaceuticals, Inc.

(1) Based on Company estimates, and recent IMS and NSP Audit data

ANI Business Development Highlights

- Announced acquisition of 31 previously marketed generic products from Teva, December 2013
- Product development partnership with Sofgen, August 2013
- Acquired royalty arrangement with Teva, June 2013
- Product development partnership with Ricon, June 2011
- Acquired Reglan™ tablets, June 2011

Business Development Focus

- In-licensing/acquisitions/alliances for development stage ANDAs, revenue generating products
- Enhancing generic product pipeline through development partnerships
- Company acquisitions

ani Pharmaceuticals, Inc.

Manufacturing Overview

ANI Manufacturing – Main Street Facility

- Location: Baudette, Minnesota
  - 52,000 square feet of manufacturing, packaging, and warehouse facilities
  - Rx solutions, suspensions, topicals, tablets, and capsules
  - DEA-licensed for Schedule II controlled substances
  - 17,000 square feet of laboratory space for product development and analytical testing

ani Pharmaceuticals, Inc.

ANI Manufacturing – IDC Road Facility

- Location: Baudette, Minnesota
  - Fully-contained high potency facility with capabilities to manufacture hormone, steroid, and oncolytic products
  - 47,000 square feet of manufacturing and packaging, and warehouse facilities
  - 100 nano-gram per eight-hour weighted average maximum exposure limit to ensure employee safety
  - DEA Schedule IIIN capability

ani Pharmaceuticals, Inc.

ANI Summary

- ANI is an integrated specialty/generic pharmaceutical firm with:
  - Profitable base business generating organic growth
  - Well capitalized balance sheet
  - Experienced management team
- ANI is focused on:
  - Internal product development
  - Partnerships/strategic alliances
  - Accretive acquisitions

ani Pharmaceuticals, Inc.

U.S. GAAP Reconciliation

ANI Pharmaceuticals, Inc. and Subsidiary
Adjusted non-GAAP EBITDA Calculation and US GAAP to Non-GAAP Reconciliation
(unaudited, in thousands)

	Three months ended December 31,		Year ended December 31,	
	2013	2012	2013	2012
Operating Income/(Loss) from Continuing Operations	$3,460	($1,017)	$898	($42)
Add back				
Depreciation and amortization	437	142	1,110	567
Add back				
Stock-based compensation	33	-	36	-
Merger-related expenses, not already added back	-	601	5,468	929
Adjusted EBITDA	$3,930	($274)	$7,512	$1,454